Essential Utilities Declares March 2025 Dividend
Get Alerts WTRG Hot Sheet
Join SI Premium – FREE
BRYN MAWR, Pa.--(BUSINESS WIRE)-- The board of directors of Essential Utilities Inc. (NYSE: WTRG) today declared a quarterly cash dividend of $0.3255 per share, payable March 3, 2025, to all shareholders of record on February 10, 2025.
The March 2025 dividend payment of $0.3255 per share represents a $0.0184, or 6.0% increase over the March 2025 dividend payment of $0.3071 per share. Essential Utilities has paid consecutive quarterly cash dividends for 79 years.
About Essential
Essential Utilities, Inc. (NYSE: WTRG) delivers safe, clean, reliable services that improve quality of life for individuals, families, and entire communities. With a focus on water, wastewater and natural gas, Essential is committed to sustainable growth, operational excellence, a superior customer experience, and premier employer status. We are advocates for the communities we serve and are dedicated stewards of natural lands, protecting more than 7,600 acres of forests and other habitats throughout our footprint.
Operating as the Aqua and Peoples brands, Essential serves approximately 5.5 million people across nine states. Essential is one of the most significant publicly traded water, wastewater service and natural gas providers in the U.S. Learn more at www.essential.co.
WTRGF
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211031369/en/
Media Contact:
David Kralle
Vice President, Public Affairs
Media Hotline: 1.877.325.3477
[email protected]
Investor Contact:
Brian Dingerdissen
Vice President, IR and Treasurer
O: 610.645.1191
[email protected]
Source: Essential Utilities Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intropy Announces $11 Million in Funding to Build the AI-Native Operating System for the Spare Parts Supply Chain
- Oasis Welcomes Significant SHiDAX Decision Affirming the Need for Substantive Fairness in Japanese M&A
- Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share